1. Introduction
Calcium ions (Ca2+) are present in low concentrations in the cytosol (~100 nM) and in high concentrations (in mM range) in both the extracellular medium and intracellular stores (mainly sarco/endo/plasmic reticulum, SR). This differential allows the calcium ion to be a ubiquitous 2nd messenger that carries information essential for cellular functions as diverse as contraction, metabolism, apoptosis, proliferation and/or hypertrophic growth. The mechanisms responsible for generating a Ca2+ signal greatly differ from one cell type to another. In the different types of vascular smooth muscle cells (VSMC), enormous variations do exist with regard to the mechanisms responsible for generating Ca2+ signal. In each VSMC phenotype (synthetic/proliferating Synthetic VSMCs have a fibroblast appearance, proliferate readily, and synthesize increased levels of various extracellular matrix components, particularly fibronectin, collagen types I and III, and tropoelastin [1]. Contractile VSMCs have a muscle-like or spindle-shaped appearance and well-developed contractile apparatus resulting from the expression and intracellular accumulation of thick and thin muscle filaments [1].
2. General aspects of calcium cycling and signaling in vascular smooth muscle cells
Besides maintaining vascular tone in mature vessels, VSMCs also preserve blood vessel integrity [2]. In other words, VSMCs are also instrumental for vascular remodeling and repair associated with VSMCs proliferation and migration. Interestingly, Ca2+ plays a central role in both physiological processes. In VSMCs, calcium signaling involves a cross-regulation of Ca2+ influx, sarcolemmal membrane signaling molecules and Ca2+ release and uptake from the sarco/endo/plasmic reticulum and mitochondria, which plays a central role in both vascular tone and integrity.
2.1. Calcium handling by the plasma membrane’s calcium channels and pumps
Membrane depolarization is believed to be a key process for the activation of calcium events in mature VSMCs. Thus, much attention has been given to uncovering the various mechanisms responsible for triggering this depolarization. Increased intra-vascular pressure of resistance arteries stimulates gradual membrane depolarization in VSMCs, increasing the probability of opening L-type high voltage-gated Ca2+ channels (Cav1.2) (LTCC) [3, 4]. Alternatively, the calcium-dependent contractile response can be induced through the activation of specific membrane receptors coupled to phospholipase C (PLC) isoforms All isoforms of PLC, catalyze the hydrolysis of phosphatidylinositol4,5-biphosphate (PIP2) to produce the intracellular messengers IP3 increase and diacylglycerol (DAG); both of which promote cytosolic Ca2+ rise through activation of plasma membrane or sarcoplasmic reticulum calcium channels.
Among voltage-insensitive calcium influx pathways, the store-operated Ca2+ channels (SOC), maintain a long-term cellular Ca2+ signal. They are activated upon a decrease of internal store Ca2+ concentration resulting from a Ca2+ release via the opening of SR Ca2+ release channels. SOC was first hypothesized in 1986 [13], a paradigm that was confirmed by the identification of its two essential regulatory components, the SR/ER located Ca2+ sensor STIM1 (stromal interaction molecule) and the Ca2+ channels Orai1 [14-17]. Upon decrease of [Ca2+] in the reticulum (<500µM), Ca2+ dissociates from STIM1; then STIM1 molecules oligomerize and translocate to specialized cortical reticulum compartments adjacent to the plasma membrane [18, 19]. There, the STIM1 cytosolic activating domains bind to and cluster the Orai proteins into an opened archaic Ca2+ channel known as Ca2+-release activated Ca2+ channel (CRAC) The CRAC is responsible for the “2h cytosolic Ca2+ increase” required to induce VSMCs proliferation [57].
The calcium signal is terminated by membrane hyper-polarization and cytosolic Ca2+ removal. First, calcium sparks resulting from the opening of sub-plasmalemmal clusters of RyR activate large-conductance Ca2+ sensitive K+ (BK) channels. Then, the resulting spontaneous transient outward currents (STOC) hyperpolarize the membrane and decrease the open probability of L-type Ca2+ channels [23]. Cytosolic calcium is extruded at the level of plasma membrane by plasma membrane Ca2+ ATPase (PMCA) and the Na+/Ca2+ exchanger (NCX) [24, 25]. The principal amount of cytosolic Ca2+ (> 70%) is re-uploaded to the internal store.
2.2. Calcium handling by the sarco/endoplasmic reticulum’s calcium channels and pumps
The initial entry of Ca2+ through plasma membrane channels triggers large Ca2+ release from the internal store via the process of Ca2+-induced Ca2+-release (CICR). The mechanism responsible for initiating Ca2+ release depends on Ca2+ sensitive SR calcium channels, the ryanodin receptor (RyR) RyR are structurally and functionally analogous to IP3R, although they are approximately twice as large and have twice the conductance of IP3R [27]; RyR channels are sensitive to store loading and IP3R channels are sensitized by the agonist-dependent formation of IP3.
Sarco/Endoplasmic Ca2+ATPases (SERCA), the only calcium transporters expressed within sarco/endoplasmic reticulum (SR), serve to actively return calcium into this organelle. In mammals, three SERCA genes ATP2A1, ATP2A2 and ATP2A3 coding for SERCA1, SERCA2 and SERCA3 isoforms respectively have been identified [35]. Each gene gives rise to a different SERCA isoform through alternative splicing (Figure 2); they all have discrete tissue distributions and unique regulatory properties, providing a potential focal point within the cell for the integration of diverse stimuli to adjust and fine-tune calcium homeostasis in the SR/ER [36]. In VSMCs, SERCA2a and the ubiquitous SERCA2b isoforms are expressed; besides vascular smooth muscle, SERCA2a is preferentially expressed in cardiac and skeletal muscles. SERCA2b differs from SERCA2a by an extension of 46 amino acids that forms an additional trans-membrane domain setting the SERCA2b C terminus in the SR lumen [37]. Functional characterization of SERCA2 isoforms performed in transfected HEK-298 cells clearly indicated that the SERCA2a isoform displays a lower affinity for Ca2+ (K0.5 = 0.985 µM) but has a higher turnover rate (ATP hydrolysis 70 s-1) compared to SERCA2b (K0.5 = 0.508 µM; 35 s-1) [38]. Diversity of SERCA isoforms in the same cell suggests that each of them could be responsible for controlling unique cell functions.
SERCA2’s activity depends on its interaction with phospholamban and is inhibitory in its de-phosphorylated form. PKA phosphorylation of phospholamban results in its dissociation from SERCA2, thus activating the Ca2+ pumps [39]. Cyclic ADP-ribose was also reported to stimulate SERCA pump activity [40].
As previously mentioned, SR Ca2+ content controls the sensitivity of SR Ca2+ channels, RyR and IP3R, as well as functioning of SOC-mediated Ca2+ entry, thereby determining the type of intracellular calcium transient. Since SOCs opening depends on Ca2+ content of the store, one may suggest that SERCA participates to its regulation. Consistent with this, SOCs open up when the leak of Ca2+ from intracellular stores is not compensated with SERCA activity; SERCA inhibitors such as thapsigargin which prevent Ca2+ uptake are commonly used to chemically induce SOC currents; several works have established that SERCA can cluster with STIM1 and Orai1 in various cellular types [41, 42].
2.3. Mechanisms of cytosolic Ca2+ oscillations in VSMC
Ca2+ oscillations are one of the ways that VSMCs respond to agonists [43-47]. These Ca2+ oscillations are maintained during receptor occupancy and are driven by an endogenous pacemaker mechanism, called the cellular Ca2+ oscillator [12, 33, 34]. Ca2+ oscillators were classified into two main types, the membrane oscillators and the cytosolic oscillators [48].
Membrane oscillators are those which generate oscillations at the cell membrane by successive membrane depolarization. In most small resistance arteries, inhibitors of plasma membrane voltage-dependent channels reduce or even abolish the membrane potential oscillations which precede rhythmical contractions. This suggests that rhythmic extracellular Ca2+ influx can be required for calcium oscillatory transient [34]. Besides, membrane oscillators greatly depend on Ca2+ entry in order to provide enough Ca2+ to charge up the intracellular stores for each oscillatory cycle. Some of the entry mechanisms characterized include the Na+/Ca2+ exchanger (NCX) operating in its reverse mode [32, 44, 49], the ATP-sensitive P2X receptor responsible for generating junctional Ca2+ transients (jCaTs) [50] or the L-type Cav1.2 channels operating as clusters in a “high open probability mode” to produce persistent Ca2+ sparklets [51]. In the case of the latter, entry of Ca2+ through these L-type channel clusters does not directly activate RyR to produce sparks, but provides the necessary amount of Ca2+ to charge up the ER and sensitize the RyR [52]. Another way of internal store reloading is achieved by the various isoforms of the transient receptor potential (TRP) ion channel family, activated directly by DAG [5, 6].
Cytosolic oscillators do not depend on the cell membrane to generate oscillations. Instead, they arise from intracellular store membrane instability. The pacemaker mechanism of cytosolic Ca2+ oscillator is based on the velocity of luminal Ca2+ loading and luminal Ca2+ content [53, 54]. The mechanism responsible for initiating Ca2+ release depends either on RyRs or IP3R activation. As soon as stores are sufficiently charged with Ca2+, the SR Ca2+ channels become sensitive to cytosolic Ca2+ and can participate to the process of Ca2+-induced Ca2+-release, which is responsible for orchestrating the regenerative release of Ca2+ from the SR/ER. Importantly, extracellular Ca2+ influx is not required for cytosolic oscillator function. Indeed, the Ca2+ oscillations can be observed in the absence of extracellular Ca2+ [43, 45, 55, 56].
Finally, it should be mentioned that SERCA proteins play a major role in the establishment of oscillatory Ca2+ transient required for phasic contractile response Phasic contractions are apparent as rapid peaks, whereas tonic contractions cause gradual changes in force that can be maintained for prolonged periods.
3. Calcium cycling and signalling in vascular smooth muscle cells
3.1. Vascular smooth muscle cell phenotype diversity
VSMCs maintain a considerable plasticity throughout life, exhibiting a diverse range of phenotypes in response to local environmental changes [58, 59]. Because studies of smooth muscle phenotype have principally focused on mechanisms which control VSMC proliferation and differentiation [58], VSMC phenotypes are classified into two main categories: the synthetic/proliferating/migratory/inflammatory and the contractile/quiescent/differentiated phenotype. In mature vessels, most VSMCs exhibit a quiescent/contractile phenotype and control the vascular tone [58, 59]. Transition of contractile VSMCs towards a proliferating/migratory/inflammatory phenotype is one of the initial mechanisms leading to pathological vascular remodeling Vascular remodeling was initially defined as the process of arterial enlargement to accommodate the plaque and maintain constant flow despite increases in atherosclerotic lesion mass. Experimental and clinical observations indicate that blood flow properties influence remodeling after angioplasty, hypertension, and flow diversion as well as atherosclerotic plaque progression [60].
Another possibility for classifying VSMCs is to categorize them based on their contractile properties which determine whether the smooth muscle is considered phasic or tonic. Phasic vascular smooth muscle refers to blood vessels displaying rhythmic contractile activity whereas tonic vascular smooth muscle refers to blood vessels displaying continuous contractions [61]. Phasic contraction is the characteristic of small resistance arteries (SRA, 20-50 µm diameters) which predominantly regulates vascular functions such as pressure and flow. Vasomotion or pulsative flow is suggested to enhance blood flow or tissue oxygenation (rev.[61])
The contractile capacities of various VSMC phenotypes are determined by expression of different isoforms of contractile proteins. For instance, phasic contractions displayed by small arteries of the heart and lung, muscular femoral artery, small mesenteric arteries and renal afferent arteriole result from the VSMC expression of the fast isoform of smooth muscle myosin heavy chain (MHC) which determines the velocity of shortening during vasomotion (rev. [61]). Of note, lent isoform of smooth muscle myosin, so called “non muscular myosin, (NM-B)” is expressed in all types of VSMCs including synthetic/proliferating VSMC; it plays a significant role in force maintenance during tonic contraction [58, 61].
Contractile response is initiated by the rise in cytosolic [Ca2+]i leading to the activation of Ca2+/calmodulin-dependent myosin light chain kinase (MLCK) [65]. However the mode of contraction, phasic or tonic, is determined by the type of cytosolic Ca2+ cycling. Different types of calcium cycling were observed in synthetic and contractile tonic or phasic VSMCs, in accordance with differential expression of calcium handling proteins [59, 60, 66].
3.2. Calcium cycling in synthetic/proliferating VSMC
The hallmark of synthetic status of VSMCs is a lack of functional proteins entity associated with the contractile response [60]; we refer to voltage activated L-type calcium channels (LTCC), SR calcium release channel RyR and “fast” isoform of SR calcium pump SERCA2a (Figure 3). In line with this, large conductance K+ channels (BKCa), which are involved in negative feedback regulation of LTCC activity through plasma membrane hyperpolarization, are also down-regulated in synthetic VSMC [67, 68]. On the other hand, the expression of the molecular entities modulating the plasma membrane Ca2+-release activated Ca2+ channel (CRAC) functioning [57, 69] are highly up-regulated; we refer to the proteins forming the CRAC complex or regulating the
In synthetic VSMC, agonist binding to PLC-coupled membrane receptors activates IP3R, resulting in a drastic increase of cytosolic Ca2+ which is weakly pumped by the “slow” calcium pump SERCA2b (the only isoform of SERCA expressed in synthetic VSMCs). The depleted store triggers the translocation of STIM1 towards the plasma membrane, which, through the opening of CRAC, induces an extracellular Ca2+ influx. This translates into a long lasting increase of cytosolic calcium critical for the activation of Ca2+-sensitive transcription factor NFAT (nuclear factor of activated T lymphocytes), required for proliferation and migration of VSMCs [56, 74]. Since these cells express contractile proteins, such as NM-B [58, 61], one may suggest that long lasting increase of cytosolic calcium can also produces tonic contraction.
Importantly enough to be mentioned, the restoration of SERCA2a expression by gene transfer in synthetic VSMCs blocks their proliferation and migration via inhibition of transcription factor NFAT [56, 75]. Molecular mechanisms of this effect are related to the prevention of functional association between STIM1 and Orai1 (CRAC protein entity) which lead to the suppression of store-operated calcium influx [56]. It is worth mentioning that SOC influx following agonist stimulation is not observed in contractile VSMCs, naturally expressing SERCA2a (Bobe & Lipskaia, unpublished data), highlighting again the importance of the SERCA isoform(s) expressed in VSMCs.
3.3. Calcium cycling in contractile tonic and phasic VSMC
In mature vessels, VSMCs mainly exhibit a tonic or phasic contractile phenotype. In contractile VSMCs extracellular calcium influx predominantly takes place through the voltage-dependent L-type calcium channel, LTCC In contractile VSMCs, NFAT can be activated by sustained Ca2+ influx (persistent Ca2+ sparklets) mediated by clusters of L-type Ca2+ channels operating in a high open probability mode [76, 77].
The “fast” calcium pump SERCA2a, specifically expressed in contractile VSMCs can be responsible for the establishment of the “cytosolic oscillator”. Several arguments are in agreement with this proposal: i) SERCA2a has a higher catalytic turnover when compared to SERCA2b due to a higher rate of de-phosphorylation and a lower affinity for Ca2+; ii) SERCA2a is absent in synthetic VSMCs, which only exhibit tonic contraction, iii) transferring the SERCA2a gene to synthetic cultured VSMCs modifies the agonist-induced calcium transient from steady-state to oscillatory mode [56]. Therefore, one might suggest that the physiological role of SERCA2a in VSMCs consists of controlling the “cytosolic oscillator”, thereby determining phasic vs tonic type of smooth muscle contraction.
Despite the fact that agonist-induced Ca2+ oscillations are a characteristic feature of the activation mechanisms of VSMCs [43-47], oscillatory type of Ca2+ transient is poorly associated with phasic contractile response. In some vessels, asynchronous oscillations of individual VSMC maintain a particular vascular tonus. However, in small resistance vessels the oscillations of groups of cells are synchronized through gap-junctions resulting in the pulsative contractile response [34, 45, 79, 80]. This oscillatory activity can be regulated by variations of neurotransmitters following sympathetic activation and can affect contractile tone through the increase of frequency, thereby increasing blood flow or tissue oxygenation [43, 45, 46, 81]. This frequency modulation could result from PKA phosphorylation of RyR, PLB and contractile proteins, as it has been established for cardiomyocytes [82-84]. Micro-vascular dysfunction, defined as the intrinsic changes in VSMCs contractility (such as reduction of frequency and shortening velocity of phasic contractions), observed in the context of cardiovascular [85, 86], may be related to reduced PKA phosphorylation of Ca2+ handling and contractile proteins, as observed in failing cardiomyocytes [82].
4. SERCA2a as a potential target for treating vascular proliferative diseases
Abundant proliferation of VSMCs is an important component of the chronic inflammatory response associated to atherosclerosis and related vascular occlusive diseases (intra-stent restenosis, transplant vasculopathy, and vessel bypass graft failure). Great efforts have been made to prevent/reduce trans-differentiation and proliferation of synthetic VSMCs. Anti-proliferative therapies including the use of pharmacological agents and gene therapy approaches are, until now, considered as a suitable approach in the treatment of these disorders [87]. Indeed, coronary stenting is the only procedure that has been proven to reduce the incidence of late restenosis after percutaneous transluminal coronary angioplasty ([88]). Nevertheless, post-interventional intra-stent restenosis, characterized by the re-narrowing of the arteries caused by VSMC proliferation, occurs in 10 to 20 % of patients. These disorders remain the major limitation of revascularization by percutaneous transluminal angioplasty and artery bypass surgery. The use of drug-eluting stents (stent eluting anti-proliferative drug) significantly reduces restenosis but impairs the re-endothelialization process and subsequently often induces late thrombosis [89, 90]. In human, trans-differentiation of contractile VSMCs towards a synthetic/proliferating inflammatory/migratory phenotype after percutaneous transluminal angioplasty appears to be a fundamental process of vascular proliferative disease [91]. In contrast, phenotypic re-differentiation of neo-intimal VSMCs after bare metal stent implantation was reported to be associated with a decline in platelet activation and inflammatory cell infiltration, and the regeneration of the endothelial cell layer [92]. Thus, defining novel molecular target(s) of DESs, that can simultaneously prevents VSMC proliferation and adverse vascular remodeling while facilitating re-endothelialization, is crucial. SERCA2a gene transfer prevents neo-intimal proliferation and intimal thickening in the rat carotid injury model by normalizing calcium cycling and inhibiting NFAT activity [75]. Furthermore, SERCA2a gene transfer prevents VSMC trans-differentiation in injured segments while allowing re-endothelialization [75]. Thus, SERCA2a can be considered as a potential and powerful target for treating vascular proliferative disease.
5. Concluding remarks
Over the last decade, great progress has been made in the understanding of the various intracellular molecular mechanisms in VSMCs which control calcium cycling and excitation/contraction or excitation/transcription coupling. VSMCs employ a great variety of Ca2+ signaling systems that are adapted to control their different contractile functions. Alterations in the expressions of Ca2+ handling molecules are closely associated with VSMC phenotype modulation. Furthermore, these changes in expression are inter-connected and each acquired or lost Ca2+ signaling molecule represents a component of signaling module functioning as a single unit.
In non-excitable synthetic VSMCs, calcium cycling results from the protein module ROC/IP3R/STIM1/ORAI1 which controls SOC influx. Agonist stimulation of synthetic VSMCs translates into a sustained increase in cytosolic Ca2+. This increase is required for the activation of NFAT downstream cellular signaling pathways inducing proliferation, migration and possibly an inflammatory response. Calcium cycling in excitable contractile VSMCs is governed by the protein module composed of ROC/LTCC/RyR2/SERCA2a and controls the contractile response. The location of particular ion channels within the smooth muscle cell with regards to internal stores, other membrane ion channels, gap junctions as well as the expression of fast isoforms of contractile proteins have a significant impact on the resulting phasic or tonic contractile response. Future studies unraveling the correlation between the dynamic changes in Ca2+ signaling protein expression and specific subcellular localization are needed to delineate the mechanisms by which Ca2+ signaling molecules produce a phasic or tonic contractile response.
6. Acknowledgments
LL is supported by AHA SDG 0930116N (USA), IL is supported by Pierre and Marie Curie University (Univ Paris 6, France) and ANR grant 11BSV103401; RB is supported by Association Française Contre les Myopathies (AFM, France); RJH is supported by NIH grants (USA) HL088434, HL080498, HL100396 and NIH/NHLBI Contract HHSN268201000045C. We thank Zela Keuylian for editing.7. Abbreviations
BK – large-conductance Ca2+ sensitive K+ channel
cADPR – cyclic Adenosine Diphosphate Ribose
CICR - Ca2+- Induced Ca2+ Release
CRAC - Ca2+- Release Activated Ca2+ Channels
DAG - Diacyl Glycerol
IP3R - sarco/endoplasmic reticulum Ca2+ channel Inositol tri-Phosphate Receptor
LTCC - voltage-dependent L-type Ca2+ channels
NCX – Na+/Ca2+ exchanger
PKA – Protein Kinase A (activated by cAMP, cyclic adenosine monophosphate)
PLC – Phospholipase C
PMCA – Plasmic Membrane Ca2+ ATPase
RyR - sarco/endoplasmic reticulum Ca2+ channel Ryanodin Receptor
SOC - Store-Operated Ca2+ Channels
SERCA - Sarco/Endoplasmic Reticulum Ca2+ ATPase
SRA - Small Resistance Arteries
SR/ER – Sarco/Endoplasmic Reticulum
STIM1 – Stromal Interaction Molecule 1, SR Ca2+ sensor
TRPC - Transient Receptor Potential ion Channel
VSMCs - Vascular Smooth Muscle Cells
References
- 1. Pauly RR, Bilato C, Cheng L, Monticone R, Crow MT. Vascular smooth muscle cell cultures. Methods Cell Biol. 1997;52:133-54.
- 2.
Yoshida T. Owens G. K. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2005Fe Feb 18;96 3 280 91 . - 3.
Harder D. R. Gilbert R. Lombard J. H. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .1987 Oct;253(4 Pt 2):F778 81 . - 4.
Fleischmann BK, Murray RK, Kotlikoff MI. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . .1994De Dec 6;91 25 11914 8 . - 5.
Saleh SN, Albert AP, Peppiatt-Wildman CM, Large WA. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . .2008Ma May 15;586 10 2463 76 . - 6.
Peppiatt-Wildman CM, Albert AP, Saleh SN, Large WA. Endothelin-1 activates a Ca2+-permeable cation channel with 3 and TRPC7 properties in rabbit coronary artery myocytes. The Journal of physiology. 2007 May 1;580(Pt.3):755-64. - 7.
Hofmann T. Obukhov A. G. Schaefer M. Harteneck C. Gudermann T. Schultz G. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . 1999 Jan 21;397 6716 259 63 . - 8.
Okada T. Inoue R. Yamazaki K. Maeda A. Kurosaki T. Yamakuni T. et al. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . 1999 Sep 24;274 39 27359 70 . - 9.
Soboloff J. Spassova M. Xu W. He L. P. Cuesta N. Gill D. L. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . 2005 Dec 2;280 48 39786 94 . - 10.
Welsh DG, Morielli AD, Nelson MT, Brayden JE. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2002Fe Feb 22;90 3 248 50 . - 11.
Haddock RE, Hill CE. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . 2002 Dec 1;545(Pt 2):615-27. - 12.
Pacemaking throughMS Imtiaz Zhao. J. Hosaka K. von der Weid. P. Y. Crowe M. van Helden D. F. 2 stores interacting as coupled oscillators via membrane depolarization. Biophysical journal. 2007 Jun 1;92 11 3843 61 . - 13.
.Putney J. W. A. model for. receptor-regulated calcium. entry 7 1 12 1986 - 14.
Liou J. Kim M. L. Heo W. D. Jones J. T. Myers J. W. Ferrell J. E. Jr et al. S. T. I. M. is 2 l. STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx. Curr Biol. 2005 Jul 12;15 13 1235 41 . - 15.
Roos J. Di Gregorio P. J. Yeromin A. V. Ohlsen K. Lioudyno M. Zhang S. et al. S. T. I. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . J Cell Biol. 2005 May 9;169 3 435 45 . - 16.
Peinelt C. Vig M. Koomoa D. L. Beck A. MJ Nadler-Huberson Koblan. et M. al Amplification. of C. R. A. C. current 1 STIM1 and CRACM1 (Orai1). Nat Cell Biol. 2006 Jul;8 7 771 3 . - 17.
Soboloff J. MA Spassova Tang. X. D. Hewavitharana T. Xu W. Gill D. L. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells J Biol Chem. 2006 Jul 28;281 30 20661 5 . - 18.
MM Wu Buchanan. J. Luik R. M. Lewis R. 2 Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . 2006 Sep 11;174 6 803 13 . - 19.
Shen W. W. Demaurex N. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . .2012Fe Feb 1;40 1 112 8 . - 20.
Yuan J. P. Lee K. P. Hong J. H. Muallem S. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . Acta Physiol (Oxf). 2012 Feb;204 2 238 47 . - 21.
Ong H. L. Cheng K. T. Liu X. Bandyopadhyay B. C. Paria B. C. Soboloff J. et al. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells J Biol Chem.2007Ma Mar 23;282 12 9105 16 . - 22.
Liao Y. Erxleben C. Yildirim E. Abramowitz J. Armstrong D. L. Birnbaumer L. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2007Ma Mar 13;104 11 4682 7 . - 23.
Nelson M. T. Cheng H. Rubart M. Santana L. F. Bonev A. D. Knot H. J. et al. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . .270 633 7 1995 - 24.
Abramowitz J. Aydemir-Koksoy A. Helgason T. Jemelka S. Odebunmi T. Seidel C. L. et al. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . .2000 May;32 5 777 89 . - 25.
EE Strehler Caride. A. J. Filoteo A. G. Xiong Y. Penniston J. T. Enyedi A. Plasma membrane. 2 ATPases as dynamic regulators of cellular calcium handling. . 2007 Mar;1099 226 36 . - 26.
Semin Cell Dev Biol.MD Bootman Collins. T. J. Peppiatt C. M. Prothero L. S. Mac Kenzie. L. De Smet P. et al. Calcium signalling--an. overview 1 12 3 10 2001 - 27.
The organisation and functions of local Ca2+ signals. J Cell Sci. 2001;114(Pt 12):2213-22.MD Bootman Lipp. P. MJ Berridge - 28.
Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol.2003 Jul;4 7 517 29 . - 29.
Lipskaia L. Lompre A. M. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells Biol Cell. 2004 Feb;96 1 55 68 . - 30.
Jaggar JH, Porter VA, Lederer WJ, Nelson MT. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells Am J Physiol Cell Physiol.2000 Feb;278(2):C235 56 . - 31.
Brain KL, Cuprian AM, Williams DJ, Cunnane TC. The sources and sequestration of2 contributing to neuroeffector Ca(2+) transients in the mouse vas deferens. The Journal of physiology. 2003 Dec 1;553(Pt 2):627-35. - 32.
Dai J. M. Kuo K. H. Leo J. M. van Breemen C. Lee C. H. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . Am J Physiol Lung Cell Mol Physiol.2006 Mar;290(3):L459 69 . - 33.
MJ Sanderson Delmotte. P. Bai Y. Perez-Zogbhi J. F. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . Proc Am Thorac Soc. 2008 Jan 1;5 1 23 31 . - 34.
Haddock RE, Hill CE. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . .2005Au Aug 1;566(Pt 3):645 EOF 656 EOF -56. - 35.
Burk S. E. Lytton J. Mac Lennan. D. H. Shull G. E. c. D. N. A. cloning functional. expression tissue m. R. N. A. distribution of. a. third organellar. 2 pump. J Biol Chem. 1989;264 31 18561 8 . - 36.
How many Ca2+ATPase isoforms are expressed in a cell type? A growing family of membrane proteins illustrated by studies in platelets. Platelets.Bobe R. Bredoux R. Corvazier E. Lacabaratz-Porret C. Martin V. Kovacs T. et al. 2005 May-Jun;16(3-4):133-50. - 37.
Campbell AM, Kessler PD, Fambrough DM. The alternative carboxyl termini of avian cardiac and brain sarcoplasmic reticulum/endoplasmic reticulum Ca(2+)-ATPases are on opposite sides of the membrane. J Biol Chem.13 267 9321 5 1992 - 38.
Ca2+ATPases in non-failing and failing heart: evidence for a novel cardiac sarco/endoplasmic reticulum Ca2+ATPase 2 isoform (SERCA2c). BiochemDally S. Bredoux R. Corvazier E. Andersen J. P. JD Clausen Dode. L. et al. Ca A. T. 2006 2006 Apr 15;395 2 249 58 . - 39.
Mac Lennan. D. H. Asahi M. Tupling A. R. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2003 Apr;986 472 80 . - 40.
Bradley K. N. Currie S. Mac Millan. D. Muir T. C. Mc Carron J. G. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . 2003 Nov 1;116(Pt 21):4291 EOF 306 EOF . - 41.
Sampieri A. Zepeda A. Asanov A. Vaca L. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . . 2009 Mar 25. - 42.
Manjarres I. M. Rodriguez-Garcia A. Alonso M. T. Garcia-Sancho J. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . Mar 25. - 43.
Iino M. Kasai H. Yamazawa T. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells cl. 1994;13 5026 31 . - 44.
Lee C. H. Poburko D. Sahota P. Sandhu J. DO Ruehlmann van Breemen. C. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells a. J Physiol.2001Au Aug 1;534(Pt 3):641 EOF 650 EOF -50. - 45.
Peng H. Matchkov V. Ivarsen A. Aalkjaer C. Nilsson H. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2001Ap Apr 27;88 8 810 5 . - 46.
Perez JF, Sanderson MJ. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells J Gen Physiol. 2005 Jun;125 6 555 67 . - 47.
Shaw FZ, Liao YF. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells J Neurophysiol.2005 May;93 5 2435 48 . - 48.
J, Rapp PE.MJ Berridge Rapp. P. E. A. comparative survey. of the. function mechanism. control of. cellular oscillators. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells J Exp Biol.81 217 79 1979 - 49.
Rebolledo A. Speroni F. Raingo J. Salemme S. V. Tanzi F. Munin V. et al. The Na. 2 exchanger is active and working inCalcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . 2006 Jan 20;339 3 840 5 . - 50.
Lamont C. Wier W. G. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . 2002 Sep 20;91 6 454 6 . - 51.
Amberg G. C. Navedo M. F. Nieves-Cintron M. JD Molkentin Santana. L. F. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2007Fe Feb 15;579(Pt 1):187 EOF 201 EOF . - 52.
Essin K. Welling A. Hofmann F. Luft F. C. Gollasch M. Moosmang S. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . 2007 Oct 1;584(Pt 1):205 EOF 19 EOF . - 53.
Berridge MJ. Calcium microdomains: organization and function. Cell Calcium. 2006 Nov-Dec;40(5-6):405-12. - 54.
Berridge MJ. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2008No Nov 1;586(Pt 21):5047 EOF 61 EOF . - 55.
DO Ruehlmann Lee. C. H. Poburko D. van Breemen C. Asynchronous 2 waves in intact venous smooth muscle. Circulation research. 2000 Mar 3;86(4):E72 9 . - 56.
Bobe R. Hadri L. Lopez J. J. Sassi Y. Atassi F. Karakikes I. et al. S. E. R. C. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . 2011 Apr;50 4 621 33 . - 57.
Berridge MJ. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2009 Jun;1793 6 933 40 . - 58.
Owens GK, Kumar MS, Wamhoff BR. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2004 Jul;84 3 767 801 . - 59.
Wamhoff BR, Bowles DK, Owens GK. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2006Ap Apr 14;98 7 868 78 . - 60.
House S. J. Potier M. Bisaillon J. Singer H. A. Trebak M. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . Pflugers Archiv : European journal of physiology.2008 Aug;456 5 769 85 . - 61.
Fisher SA. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . Physiol Genomics.2010No Nov 15;42A(3):169-87. - 62.
Mol Interv.Nilsson H. Aalkjaer C. Vasomotion mechanisms. physiological importance. 2003 Mar;3 2 79 89 . - 63.
Parthimos D. Haddock R. E. CE Hill Griffith. T. M. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2007Se Sep 1;93 5 1534 56 . - 64.
Figueroa XF, Isakson BE, Duling BR. Connexins: gaps in our knowledge of vascular function. ).2004 Oct;19 277 84 . - 65.
Wray S. Burdyga T. Noble K. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2005 Sep-Oct;38(3-4):397 EOF 407 EOF . - 66.
Thorneloe KS, Nelson MT. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells Can J Physiol Pharmacol.2005 Mar;83 3 215 42 . - 67.
Molecular cloning and characterization of the intermediate-conductance Ca(2+)-activated K(+) channel in vascular smooth muscle: relationship between K(Ca) channel diversity and smooth muscle cell function. Circulation research.Neylon C. B. Lang R. J. Fu Y. Bobik A. Reinhart P. H. 1999Oc Oct 29;85(9):e33 43 . - 68.
Kohler R. Wulff H. Eichler I. Kneifel M. Neumann D. Knorr A. et al. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2003Se Sep 2;108 9 1119 25 . - 69.
Lewis RS. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2007Ma Mar 15;446 7133 284 7 . - 70.
Berra-Romani R. Mazzocco-Spezzia A. Pulina M. V. Golovina V. 2 Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . Am J Physiol Cell Physiol. 2008 Sep;295(3):C779 90 . - 71.
Potier M. Gonzalez J. C. Motiani R. K. Abdullaev I. F. Bisaillon J. M. Singer H. A. et al. Evidence for. S. T. I. 1 and Orai1-dependent store-operated calcium influx through ICRAC in vascular smooth muscle cells: role in proliferation and migration. The : official publication of the Federation of American Societies for Experimental Biology. 2009 Aug;23 8 2425 37 . - 72.
Bergdahl A. Gomez M. F. Wihlborg A. K. Erlinge D. Eyjolfson A. Xu S. Z. et al. Plasticity of. T. R. P. C. expression in. arterial smooth. muscle correlation. with store-operated. 2 entry. Cell physiology. 2005 Apr;288(4):C872 80 . - 73.
Kumar B. Dreja K. Shah S. S. Cheong A. Xu S. Z. Sukumar P. et al. Upregulated T. R. P. 1 channel in vascular injury in vivo and its role in human neointimal hyperplasia. . 2006 Mar 3;98 4 557 63 . - 74.
Dolmetsch RE, Lewis RS, Goodnow CC, Healy JI. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . 1997;386 6627 855 8 . - 75.
Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res.Lipskaia L. del Monte F. Capiod T. Yacoubi S. Hadri L. Hours M. et al. 2005Se Sep 2;97 5 488 95 . - 76.
Br J Pharmacol.Aalkjaer C. Nilsson H. Vasomotion cellular. background for. the oscillator. for the. synchronization of. smooth muscle. cells 2005 Mar;144 5 605 16 . - 77.
Wray S. Burdyga T. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . .2010 Jan;90 1 113 78 . - 78.
Bartlett IS, Crane GJ, Neild TO, Segal SS. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . .2000 Nov-Dec;37 6 568 75 . - 79.
Adrenergic stimulation of rat resistance arteries affectsMauban J. R. Lamont C. Balke C. W. Wier W. G. 2 sparks, Ca(2+) waves, and Ca(2+) oscillations. Heart and circulatory physiology. 2001 May;280(5):H2399 405 . - 80.
Lamboley M. Schuster A. Beny J. L. Meister J. J. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells . Heart and circulatory physiology.2003 Aug;285(2):H562 9 . - 81.
Kuo K. H. Dai J. Seow C. Y. Lee C. H. van Breemen C. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells Am J Physiol Lung Cell Mol Physiol. 2003 Dec;285(6):L1345 53 . - 82.
Lipskaia L. Chemaly E. R. Hadri L. Lompre A. M. Hajjar R. J. Sarcoplasmic reticulum. 2 ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther. 2010 Jan;10 1 29 41 . - 83.
Telokin mediates Ca2+-desensitization through activation of myosin phosphatase in phasic and tonic smooth muscle. J Muscle Res Cell Motil.Choudhury N. AS Khromov Somlyo. A. P. Somlyo A. V. 8 25 657 65 2004 - 84.
Schubert R. Lehmann G. Serebryakov V. N. Mewes H. Hopp H. H. c. A. M. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .1999 Sep;277(3 Pt 2):H1145 55 . - 85.
Zhang H. Fisher S. A. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2007Ma Mar 16;100 5 730 7 . - 86.
Payne M. C. Zhang H. Y. Shirasawa Y. Koga Y. Ikebe M. Benoit J. N. et al. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells Heart and circulatory physiology.2004 May;286(5):H1801 10 . - 87.
Andres V. Castro C. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells Curr Vasc Pharmacol.2003 Mar;1 1 85 98 . - 88.
Foley D. P. Melkert R. Umans V. A. de Jaegere P. P. Strikwerda S. de Feyter P. J. et al. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .1995 Oct;16 10 1331 46 . - 89.
Luscher T. F. Steffel J. Eberli F. R. Joner M. Nakazawa G. Tanner F. C. et al. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells .2007Fe Feb 27;115 8 1051 8 . - 90.
Effect of angiotensin II onFukuta Y. Joshizumi M. Kitagawa T. Hori T. Katoh I. Houchi H. et al. 2 2+ efflux from freshly isolated adult rat cardiomyocytes. Possible involvement of Na+/ Ca 2+ exchanger. Biochem Pharmacol. 1998;55 481 7 . - 91.
Ueda M. Becker A. E. Naruko T. Kojima A. Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells Coron Artery Dis.1995 Jan;6 1 71 81 . - 92.
J Atheroscler Thromb.Nakagawa M. Naruko T. Ikura Y. Komatsu R. Iwasa Y. Kitabayashi C. et al. A. decline in. platelet activation. inflammatory cell. infiltration is. associated with. the phenotypic. redifferentiation of. neointimal smooth. muscle cells. after bare-metal. stent implantation. in acute. coronary syndrome. 2010Ju Jul 30;17 7 675 87 .
Notes
- Synthetic VSMCs have a fibroblast appearance, proliferate readily, and synthesize increased levels of various extracellular matrix components, particularly fibronectin, collagen types I and III, and tropoelastin [1].
- Contractile VSMCs have a muscle-like or spindle-shaped appearance and well-developed contractile apparatus resulting from the expression and intracellular accumulation of thick and thin muscle filaments [1].
- All isoforms of PLC, catalyze the hydrolysis of phosphatidylinositol4,5-biphosphate (PIP2) to produce the intracellular messengers IP3 increase and diacylglycerol (DAG); both of which promote cytosolic Ca2+ rise through activation of plasma membrane or sarcoplasmic reticulum calcium channels.
- The CRAC is responsible for the “2h cytosolic Ca2+ increase” required to induce VSMCs proliferation [57].
- RyR are structurally and functionally analogous to IP3R, although they are approximately twice as large and have twice the conductance of IP3R [27]; RyR channels are sensitive to store loading and IP3R channels are sensitized by the agonist-dependent formation of IP3.
- Phasic contractions are apparent as rapid peaks, whereas tonic contractions cause gradual changes in force that can be maintained for prolonged periods.
- Vascular remodeling was initially defined as the process of arterial enlargement to accommodate the plaque and maintain constant flow despite increases in atherosclerotic lesion mass. Experimental and clinical observations indicate that blood flow properties influence remodeling after angioplasty, hypertension, and flow diversion as well as atherosclerotic plaque progression [60].
- Vasomotion or pulsative flow is suggested to enhance blood flow or tissue oxygenation (rev.[61])
- In contractile VSMCs, NFAT can be activated by sustained Ca2+ influx (persistent Ca2+ sparklets) mediated by clusters of L-type Ca2+ channels operating in a high open probability mode [76, 77].